InterMune To Release Fourth Quarter Financial Results On February 21

     InterMune To Release Fourth Quarter Financial Results On February 21

PR Newswire

BRISBANE, Calif., Feb. 11, 2013

BRISBANE, Calif., Feb. 11, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN)
today announced that it will release its fourth quarter and full-year 2012
financial results at the close of the U.S. markets on Thursday, February 21,
2013. A live conference call and webcast will be hosted by InterMune at 4:30
p.m. Eastern time that same day.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Interested investors and others may participate in the conference call by
dialing 800-891-8257 (U.S.) or
+1 212-271-4651 (international), conference ID# 21648922. A replay of the
webcast and teleconference will be available on the company's website
approximately three hours after the call. To access the live webcast, please
log on to the company's website at www.intermune.com at least 15 minutes prior
to the start of the call to ensure adequate time for any software downloads
that may be required.

A telephonic replay will be available for 10 business days following the call
and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140
(international), and entering the conference ID# 21648922.

About InterMune
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan fibrotic
diseases. In pulmonology, InterMune is focused on therapies for the treatment
of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.
Pirfenidone, the only medicine approved for IPF anywhere in the world, is
approved for marketing by InterMune in the EU and Canada as Esbriet^® and is
currently in a Phase 3 clinical trial to support regulatory registration in
the United States. InterMune's research programs are focused on the discovery
of targeted, small-molecule therapeutics and biomarkers to treat and monitor
serious pulmonary and fibrotic diseases.For additional information about
InterMune and its R&D pipeline, please visit www.intermune.com.

SOURCE InterMune, Inc.

Website: http://www.intermune.com
Contact: Jim Goff, InterMune, Inc., +1-415-466-2228, jgoff@intermune.com
 
Press spacebar to pause and continue. Press esc to stop.